NASDAQ:IMMU - Immunomedics Stock Price, Forecast & News

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.05. The biopharmaceutical company earned $0.30 million during the quarter, compared to analyst estimates of $0.18 million. During the same period in the previous year, the business earned ($0.68) EPS. View Immunomedics' Earnings History.

9 analysts have issued 1-year target prices for Immunomedics' shares. Their forecasts range from $16.00 to $40.00. On average, they expect Immunomedics' share price to reach $27.33 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price. View Analyst Price Targets for Immunomedics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

News stories about IMMU stock have trended very negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunomedics earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Immunomedics.

Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Seattle Genetics (SGEN), NVIDIA (NVDA), ImmunoGen (IMGN), Exelixis (EXEL), Micron Technology (MU), Iovance Biotherapeutics (IOVA), Netflix (NFLX) and ACADIA Pharmaceuticals (ACAD).

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional investors include Boxer Capital LLC (4.37%), State Street Corp (3.51%), ArrowMark Colorado Holdings LLC (2.79%), FMR LLC (2.39%), Janus Henderson Group PLC (1.92%) and Jennison Associates LLC (1.56%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Bryan Ball, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., Pictet Asset Management Ltd., Janus Henderson Group PLC, UBS Group AG, Sectoral Asset Management Inc, Marshall Wace LLP and Peregrine Capital Management LLC. View Insider Buying and Selling for Immunomedics.

IMMU stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Partner Fund Management L.P., Boxer Capital LLC, Franklin Resources Inc., Goldman Sachs Group Inc., Fiera Capital Corp and Renaissance Technologies LLC. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $16.00.

Immunomedics has a market capitalization of $3.09 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics.

The official website for Immunomedics is http://www.immunomedics.com/.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]